Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)

NCT05930275 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05930275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05930275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
February 19, 2024
Completion date
September 30, 2028
Enrollment
1,200 (estimated)
Sites
180

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease